Paris, France 4/1/14; Paris, France 4/7/14—Molecular diagnostics firm Genomic Vision has completed its IPO, listing its shares on the Euronext Paris stock exchange (see IBO 3/31/14). The company’s shares began trading on April 7 at a price of €15.00 ($20.55 = €0.73= $1) per share, the middle of the expected pricing range. The offering raised a total of €23.0 million ($31.5 million) prior to the exercise of the overallotment option. Genomic’s market capitalization is €64 million ($88 million). “Thanks to the funds we have raised, Genomic Vision can confidently begin a new phase in its development based on the marketing of its tests in Europe, the enhanced throughput of its technological platform and the designing of new tests based on its innovative technology—unique in the world—for diagnosing genetic diseases and hereditary cancers,” stated Genomics cofounder and Chairman Aaron Bensimon. Genomic plans to use the proceeds to develop sales in Europe as well as to finance ongoing projects to improve the platform and for R&D.